Post-COVID-19 cryptosporidiosis: A serious risk or mere association?

Post-COVID-19 conditions encompass a wide range of health problems, including enteritis, but their association with parasitic infections has not yet been investigated. This study analyzed gastrointestinal symptoms, medical histories, fecal Cryptosporidium oocysts, and the history of COVID-19 infection in patients who attended the Faculty of Medicine, Cairo University, from January to July 2021. Fecal biomarkers, including H. pylori, occult blood, fecal calprotectin (FCAL), and TNF-a, were measured, and Cryptosporidium spp. genotypes were molecularly characterized among post-COVID-19 patients using RFLP. Preliminary results from 210 post-COVID-19 patients revealed that group 1 (Cryptosporidiumpositive) (n = 49) and group 2 (Cryptosporidium-negative) (n = 161) showed no significant difference in the prevalence rate of diabetes mellitus (DM). While group 2 was linked to diarrhea, only infections with Cryptosporidium post-COVID-19 were related to chronic diarrhea, vomiting, and weight loss. A total of 220 healthy subjects served as negative controls. Administering azithromycin, hydroxychloroquine, and ivermectin was significantly related to an increased risk of Cryptosporidium infection in group 1, whereas only azithromycin was more frequently recorded in group 2. Antioxidant supplementation insignificantly affected the incidence of cryptosporidiosis. Cryptosporidiosis with a history of COVID-19 was linked to H. pylori infections, increased inflammatory biomarkers (FCAL and TNF-a), and occult blood when compared with group 2. Cryptosporidium genotype 1 was the most commonly occurring subset in individuals with post-COVID-19. The findings demonstrated that aggravating gastrointestinal manifestations, increased fecal biomarkers and anti-COVID-19 therapeutic interventions are significantly related to the existence of Cryptosporidium oocysts in patients with post-COVID-19, indicating the predominance of.

Post-COVID-19 cryptosporidiosis: A serious risk or mere association?

@#Post-COVID-19 conditions encompass a wide range of health problems, including enteritis, but their association with parasitic infections has not yet been investigated. This study analyzed gastrointestinal symptoms, medical histories, fecal Cryptosporidium oocysts, and the history of COVID-19 infection in patients who attended the Faculty of Medicine, Cairo University, from January to July 2021. Fecal biomarkers, including H. pylori, occult blood, fecal calprotectin (FCAL), and TNF-a, were measured, and Cryptosporidium spp. genotypes were molecularly characterized among post-COVID-19 patients using RFLP. Preliminary results from 210 post-COVID-19 patients revealed that group 1 (Cryptosporidiumpositive) (n = 49) and group 2 (Cryptosporidium-negative) (n = 161) showed no significant difference in the prevalence rate of diabetes mellitus (DM). While group 2 was linked to diarrhea, only infections with Cryptosporidium post-COVID-19 were related to chronic diarrhea, vomiting, and weight loss. A total of 220 healthy subjects served as negative controls. Administering azithromycin, hydroxychloroquine, and ivermectin was significantly related to an increased risk of Cryptosporidium infection in group 1, whereas only azithromycin was more frequently recorded in group 2. Antioxidant supplementation insignificantly affected the incidence of cryptosporidiosis. Cryptosporidiosis with a history of COVID-19 was linked to H. pylori infections, increased inflammatory biomarkers (FCAL and TNF-a), and occult blood when compared with group 2. Cryptosporidium genotype 1 was the most commonly occurring subset in individuals with post-COVID-19. The findings demonstrated that aggravating gastrointestinal manifestations, increased fecal biomarkers and anti-COVID-19 therapeutic interventions are significantly related to the existence of Cryptosporidium oocysts in patients with post-COVID-19, indicating the predominance of.

A STUDY OF THE ASSESSMENT OF SERUM ADROPIN LEVEL AS A RISK FACTOR OF ISCHAEMIC HEART DISEASE IN TYPE 2 DIABETES MELLITUS CASES.

Adropin is a peptide hormone that was first identified in 2008 and was first thought to have a significant role in the balance of fatty acids and glucose in peripheral tissues. We look at the relationship between adropin and diabetes individuals' ischemic heart disease. The objective of the study is to evaluate the serum adropin level as a potential indicator of ischemic heart disease in people with type 2 diabetes mellitus. The 90 participants in this case-control study were split into three groups: Group (I) consisted of 30 T2DM patients with ischemic heart disease Group (II) consisted of 30 T2DM patients without ischaemic heart disease Group (III) consisted of 30 healthy persons as the control group. HbA1c, lipid profile (cholesterol, triglycerides, LDL-C, HDL), HOMA IR serum creatinine, AST, ALT, and serum adropin were also evaluated. Fasting plasma glucose, 2h postprandial plasma glucose, Carotid artery intimal thickness using ultrasound, and Carotid artery intimal thickness were also measured. Patients with diabetes who did not have ischemic heart disease had a statistically significant rise in serum Adropin hormone (p value 0.001), with values of (26.867 10.037) ng/L and (87.500 40.509) ng/L, respectively. Additionally, there was a bad correlation between serum adropin and CIMT and fasting insulin. Assessment of serum adropin levels may serve as a risk indicator for the emergence of ischemic heart disease in people with type 2 diabetes mellitus.